Is late luminal loss an accurate predictor of the clinical effectiveness of drug-eluting stents in the coronary arteries?

被引:22
|
作者
Agostoni, P [1 ]
Valgimigli, M
Abbate, A
Cosgrave, J
Pilati, M
Biondi-Zoccai, GGL
机构
[1] AZ Middelheim, Antwerp Cardiovasc Inst Middleheim, Antwerp, Belgium
[2] Erasmus MC, Thoraxctr, Rotterdam, Netherlands
[3] Virginia Commonwealth Univ, Med Coll Virginia, Richmond, VA 23298 USA
[4] Hosp San Raffaele, Intervent Cardiol Unit, I-20132 Milan, Italy
[5] Policlin S Donato, Hemodynam & Cardiovasc Radiol Serv, Milan, Italy
[6] Univ Verona, Dept Cardiol, I-37100 Verona, Italy
来源
AMERICAN JOURNAL OF CARDIOLOGY | 2006年 / 97卷 / 05期
关键词
D O I
10.1016/j.amjcard.2005.09.095
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Late luminal loss after percutaneous coronary intervention, although not normally distributed, has been shown to be monotonically correlated with the probability of binary angiographic restenosis after drug-eluting stent implantation. A recently proposed method has been shown to predict the restenosis rate after sirolimus-eluting stent and paclitaxel-eluting stent implantation using a power transformation of the value of late loss obtained after implantation of the 2 stent types. We used the same method to compute and compare restenosis rates from late loss values observed in the "head-to-head" randomized sirolimus-eluting stent versus paclitaxel-eluting stent comparisons available thus far. Our results showed that the model proposed has a poor overall ability to predict the real incidence and relative risk of restenosis because the use of late loss as an end point tended to overestimate the difference in restenosis, and the derived effect estimate of 1 stent compared with that of the other seemed to be overemphasized with respect to the real risk. We thus believe that further investigations are needed to appraise the real clinical effect of late loss and its reliability as an end point in direct comparative drug-eluting stent trials before its use can be recommended as a clinical surrogate. (C) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:603 / 605
页数:3
相关论文
共 50 条
  • [21] Cost-effectiveness of drug-eluting coronary stents in Quebec, Canada
    Brophy, JM
    Erickson, LJ
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2005, 21 (03) : 326 - 333
  • [22] Drug-Eluting or Bare-Metal Stents in Large Coronary Arteries REPLY
    Kaiser, Christoph
    Pfisterer, Matthias
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (12): : 1180 - 1180
  • [23] Effectiveness of Drug-Eluting Stents versus Bare-Metal Stents in Large Coronary Arteries in Patients with Acute Myocardial Infarction
    Sim, Doo Sun
    Jeong, Myung Ho
    Ahn, Youngkeun
    Kim, Young Jo
    Chae, Shung Chull
    Hong, Taek Jong
    Seong, In Whan
    Chae, Jei Keon
    Kim, Chong Jin
    Cho, Myeong Chan
    Seung, Ki Bae
    Park, Seung Jung
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2011, 26 (04) : 521 - 527
  • [24] Drug-Eluting versus Bare-Metal Stents in Large Coronary Arteries
    Kaiser, Christoph
    Galatius, Soeren
    Erne, Paul
    Eberli, Franz
    Alber, Hannes
    Rickli, Hans
    Pedrazzini, Giovanni
    Hornig, Burkhard
    Bertel, Osmund
    Bonetti, Piero
    De Servi, Stefano
    Brunner-La Rocca, Hans-Peter
    Ricard, Ingrid
    Pfisterer, Matthias
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (24): : 2310 - 2319
  • [25] Drug-coated balloons and drug-eluting stents: clinical effectiveness revisited
    Fanelli, F.
    Cannavale, A.
    JOURNAL OF CARDIOVASCULAR SURGERY, 2014, 55 (05): : 625 - 630
  • [26] Drug-eluting stents and late stent thrombosis
    Webster, Markw W. I.
    Ormiston, John A.
    LANCET, 2007, 370 (9591): : 914 - 915
  • [27] Effectiveness and safety of drug-eluting stents in Ontario
    Tu, Jack V.
    Bowen, James
    Chiu, Maria
    Ko, Dennis T.
    Austin, Peter C.
    He, Yaohua
    Hopkins, Robert
    Tarride, Jean-Eric
    Blackhouse, Gord
    Lazzam, Charles
    Cohen, Eric A.
    Goeree, Ron
    NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (14): : 1393 - 1402
  • [28] Late loss is a robust surrogate for clinical Restenosis in coronary drug-eluting stent trials
    Mauri, L
    Candia, S
    Hughes, MD
    Kuntz, RE
    CIRCULATION, 2005, 112 (17) : U799 - U799
  • [29] Downstream coronary effects of drug-eluting stents
    Krasuski, Richard A.
    Cater, George M.
    Devendra, Ganesh P.
    Wolski, Kathy
    Shishehbor, Mehdi H.
    Nissen, Steven E.
    Oberti, Carlos
    Ellis, Stephen G.
    AMERICAN HEART JOURNAL, 2011, 162 (04) : 764 - U225
  • [30] Novel drug-eluting stents for coronary revascularization
    Gogas, Bill D.
    McDaniel, Michael
    Samady, Habib
    King, Spencer B., III
    TRENDS IN CARDIOVASCULAR MEDICINE, 2014, 24 (07) : 305 - 313